<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03909594</url>
  </required_header>
  <id_info>
    <org_study_id>2018-08-05</org_study_id>
    <nct_id>NCT03909594</nct_id>
  </id_info>
  <brief_title>Bubiket Study: Ultrasound Guided Fascia Iliaca Nerve Block With Bupivacaine and Adjuvant Ketamine vs. Bupivacaine Alone</brief_title>
  <official_title>Ultrasound Guided Fascia Iliaca Nerve Block With Bupivacaine and Adjuvant Ketamine vs. Bupivacaine Alone in Patients With Hip or Femur Fracture: a Double Blind Randomized Clinical Trial (BupiKet)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonios Likourezos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project is meant to evaluate the effect of a combination of medications (Bupivacaine +&#xD;
      Ketamine) used in an ultra-sound guided nerve block for patients presenting to the Emergency&#xD;
      Department (ED) with hip and/or femur fractures. The goal is to see whether the combination&#xD;
      of these two medications will result in greater and longer-lasting pain relief,&#xD;
      longer-lasting motor and sensory block and overall less need for opioid rescue analgesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN&#xD;
&#xD;
      Subjects: Patients aged 18 years and older with isolated hip or femur fracture confirmed on&#xD;
      x-ray.&#xD;
&#xD;
      DESIGN:&#xD;
&#xD;
      A randomized double-blind prospective superiority trail.&#xD;
&#xD;
        -  Each patient will receive Morphine for analgesia prior to regional nerve block.&#xD;
&#xD;
             -  Patients &lt; 65 years will receive Morphine 0.1 mg/kg every four hours as needed for&#xD;
                2 doses&#xD;
&#xD;
             -  Patients &gt; 65 years will receive Morphine 0.05 mg/kg every four hours as needed for&#xD;
                2 doses&#xD;
&#xD;
        -  Treatment group: will receive an ultrasound guided regional nerve block with Bupivacaine&#xD;
           (0.5% or 5 mg/ml) 2.5 mg/kg (max dose 175 kg) + Ketamine (50 mg/ml) 2 mg/kg. Each&#xD;
           patient will be given a volume of 40 mL - this will be a mixture of Bupivacaine,&#xD;
           Ketamine and 0.9% NS to make up the full 40 ml.&#xD;
&#xD;
        -  Control group: will receive an ultrasound guided regional nerve block with Bupivacaine&#xD;
           0.5% only. Each patient will be given a volume of 40 ml - this will be a mixture of&#xD;
           Bupivacaine and 0.9% NS to make up the full volume of 40 mL&#xD;
&#xD;
        -  The patients will be followed with respect to accrual time, follow up time, and total&#xD;
           time of the block as well as a need for rescue analgesia as follows: every 15 minutes&#xD;
           for the first hour; every 30 minutes for the next hour; every 1 hour for next 4 hours;&#xD;
           every 4 hours for next 18 hours with end point of 24 hours or up until they are taken to&#xD;
           surgery, whichever comes first.&#xD;
&#xD;
        -  Evaluation of the sensory blocks: will be performed every 5 minutes after administration&#xD;
           of the local anesthetic. The sensory block will be quantified as: 0 = Anesthesia (no&#xD;
           sensation), 1 = Analgesia (decreased [dull] sensation), and 2 = no block (normal&#xD;
           sensation), by using the pinprick test and comparing with the contralateral limb. The&#xD;
           time elapsed from the injection to the onset of analgesia in the central sensory region&#xD;
           of femoral nerve block will be taken as time of onset of the sensory block.&#xD;
&#xD;
        -  Rescue Analgesia: If pain is not relieved and the participant requires rescue analgesia&#xD;
           a weight-based dose of Morphine will be given at 0.1 mg/kg.&#xD;
&#xD;
      In addition, an antidote (lipid emulsion) that will be given to patients who need it when&#xD;
      they develop severe side effects.&#xD;
&#xD;
      DATA COLLECTION:&#xD;
&#xD;
      Patient demographic, clinical and injury information, pain score, onset of motor and sensory&#xD;
      block, rescue analgesia and side effects/adverse events will be collected by using a data&#xD;
      collection form by trained research assistant and associates.&#xD;
&#xD;
      DATA ANALYSIS:&#xD;
&#xD;
      Statistical Analyses will include frequency distributions, t-test and chi-square for&#xD;
      comparison between and within the groups and Cox Linear Regression Analysis. P&lt;.05 will&#xD;
      denote statistical significance. Statistical analyses will be conducted via SPSS version 24.&#xD;
      Antonios Likourezos or equivalent will perform the statistical analyses.&#xD;
&#xD;
      EXPECTED OUTCOMES:&#xD;
&#xD;
      PRIMARY OUTCOME: time to first rescue analgesia post-regional nerve blockade in each group&#xD;
&#xD;
      SECONDARY OUTCOMES:&#xD;
&#xD;
      â€¢ Change in pain score as measured by Visual Analog Scale: Patient to be approached at the&#xD;
      following intervals: every 15 minutes for the first hour; every 30 minutes for the next hour;&#xD;
      every 1 hour for next 4 hours; every 4 hours for next 18 hours with end point of 24 hours or&#xD;
      up until they are taken to surgery, whichever comes first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The COVID Pandemic delayed start of study and currently the investigators are not interested in&#xD;
    conducting the study.&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a randomized double blind study - - All the pharmacist and research manager</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>time to first rescue analgesia post-regional nerve blockade</measure>
    <time_frame>0-24 hours</time_frame>
    <description>The difference in time from administration of pain medication to rescue analgesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score at 30 minutes</measure>
    <time_frame>30 minutes</time_frame>
    <description>The pain score at 30 minutes at an 11 point Likert Numeric Rating Scale (0 = no pain; 5=moderate pain, and 10 = very severe pain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pain, Musculoskeletal</condition>
  <arm_group>
    <arm_group_label>Nerve Block with Bupivacaine an</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive an ultrasound guided regional nerve block with Bupivacaine (0.5% or 5 mg/ml) 2.5 mg/kg (max dose 175 kg) + Ketamine (50 mg/ml) 2 mg/kg. Each patient will be given a volume of 40 mL - this will be a mixture of Bupivacaine, Ketamine and 0.9% NS to make up the full 40 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nerve Block with Bupivacaine al</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive an ultrasound guided regional nerve block with Bupivacaine 0.5% only. Each patient will be given a volume of 40 ml - this will be a mixture of Bupivacaine and 0.9% NS to make up the full volume of 40 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Bupivacaine</description>
    <arm_group_label>Nerve Block with Bupivacaine al</arm_group_label>
    <arm_group_label>Nerve Block with Bupivacaine an</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine</description>
    <arm_group_label>Nerve Block with Bupivacaine an</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years and older&#xD;
&#xD;
          -  Presenting with isolated hip or femur fracture confirmed on x-ray.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Polytrauma&#xD;
&#xD;
          -  Unstable vitals signs&#xD;
&#xD;
          -  Allergy to Bupivacaine or Ketamine&#xD;
&#xD;
          -  Inability to give consent&#xD;
&#xD;
          -  Altered mental status&#xD;
&#xD;
          -  Greater than 100kg&#xD;
&#xD;
          -  Known end stage renal disease or hepatic dysfunction&#xD;
&#xD;
          -  Received &gt; 2 doses of Morphine in ER prior to regional nerve block&#xD;
&#xD;
          -  Patients with failed nerve block (30 minute onset)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Motov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 4, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Antonios Likourezos</investigator_full_name>
    <investigator_title>Research Manager; Co-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03909594/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

